No current evidence supporting risk of using Ibuprofen in patients with COVID-19

Int J Clin Pract. 2020 Oct;74(10):e13576. doi: 10.1111/ijcp.13576.

Abstract

SARS‐CoV‐2 is a novel RNA virus that infects cells expressing the angiotensin‐converting enzyme (ACE2) receptor and is associated with an acute respiratory disease named COVID‐19. It has been hypothesized that ACE2 expression can be increased by Ibuprofen leading to a higher risk for severe COVID‐19 (1). Despite the reasonable mechanistic background and results from studies suggesting that Ibuprofen may be associated with complications of community‐acquired pneumonia in children (2,3), there is no current evidence that this NSAID aggravates a SARS‐CoV‐2 infection in any age group.

Publication types

  • Letter
  • Comment

MeSH terms

  • Anti-Inflammatory Agents, Non-Steroidal
  • Betacoronavirus
  • COVID-19
  • Coronavirus Infections*
  • Diabetes Mellitus*
  • Humans
  • Hypertension*
  • Ibuprofen
  • Pandemics*
  • Pneumonia, Viral*
  • SARS-CoV-2

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Ibuprofen